Drug information

Bupropion
Indication: Melancholia, excipient of banning cigarettes
Product COA: demanded product COA
Consulting Phone Line: 07-591-9568
Product Instruction
Bupropion is one kind of aminoketone derivative that possesses anti-melancholy function. Meanwhile, it is also an excipient of banning cigarettes. Its mechanism is still not clear. The American neurology medical association will categorize this medicine as dopamine-norepinephrine reuptake inhibitor this medicine according to the treatment rules in 2000.

Bans of Product
  1. People who are allergic to this medicine.
  2. Epilepsy patients.
  3. Patients who had or have polyphagia or nervous anorexia.
  4. It can not be used with monoamine oxidase inhibitors (MAOIs). To begin using bupropion at least time space between fourteen days, after stopping using MAOIs.

Special Warning and Attention of Usage
  1. Patients who have a bout of epilepsy during taking bupropion should stop taking this medicine and never use again.
  2. To reduce probabilities of epileptic paroxysm should follow the procedures below: The daily dosage can not surpass 400 milligrams, the daily dosage should be divided into two sizes for taking, and the single dosage can not surpass 200 milligrams while increasing dose slowly.
  3. Possible situations that increase probabilities of epileptic paroxysm: Epilepsy medical history, forehead flesh wound, tumour of central nervous system, liver cirrhosis, excessive intake of ethyl alcohol or sedative, drugs abusing, irritants of central nervous system, diabetes patients, and intake medicines that decrease percentages of the epileptic paroxysm.
  4. Patients who are lack of livers or kidney functions should reduce dosage and intake frequency while using treatments of bupropion.
  5. Patients who use the combination of bupropion and Nicotine substitution instead treatments should detect blood pressure frequently.

Medical Correlation and Other Correlations
  1. Bupropion mainly becomes hydroxybupropion due to the metabolism of CYP2B6. Therefore it should be watched out while using other medicines that might affect bupropion, such as orphenadrine and cyclophosphamide.
  2. Caution should be aware for higher paroxysm of side effects while using with levodopa.
  3. Bupropion and hydroxybupropion are CYP2D6 inhibitors. Therefore, the lower dosage should be started with while using with some β-blockers, antiarrhythmic agents, SSRIs, TCAs, anti-mental disordered drugs.

Unwilling Respondence
Common unwilling respondences can be over-excitement, mouth dryness, insomnia, headache, disgusting/vomits, constipation, shivers and etc. Epileptic paroxysm rate is approximately 0.1% while Wellbutrin SR dosage reaches 300 milligrams/day, and is 0.4% while reaching 400 milligrams/day.
 
 
Clopidogrel Bisulfate
Indication: to reduce the recent period of stroke paroxysm, myocardial infarction or the gruel shape arteriosclerosis events of peripheral artery blood vessel diseases, such as myocardial infarction, stroke or deaths because of other mutation of blood vessel pathology. The non-ST section rise of the acute crown heart diseases (unstable angina pectoris and non-Q wave mode myocardial infarction) can be reduced for events of patients having gruel of shape artery embolism while taking with aspirin.
Product COA: demanded product COA
Consulting Phone Line: 07-591-9568

Product Instruction
Clopidogrel belongs to one type of anti-blood platelet agent. Blood platelets are extremely small, that are smaller than red blood cells and white blood cells. When they condense together, blood coagulation will be formed. The anti-blood platelet agent can prevent blood platelet from gathering, thus reduce the opportunity of blood coagulation (this process is called the formation of thrombus). This product can prevent the formation of blood clot (thrombus) inside the hardened blood vessel (artery). This is the procedure of formatting so-called gruel shape artery thrombus that can cause accidents of the gruel shape artery embolism, such as stroke, heart disease or death.


Bans of Product
  1. Patients are allergic to major components of this medicine or other non-active constituents.
  2. Patients are lack of liver functions seriously.
  3. Patients are having haemorrhage, such as digesting ulcer or skull internal haemorrhage.
  4. People are having colostrum.
Special Warning and Attention of Usage
  1. Blood cell counts should be detected frequently during treatments because of unwilling respondences and risks of haemorrhage in aspect of haematology. As well, detection should be carried out properly and immediately while clinical symptom of haematology is occurred.
  2. Clopidogrel should be carefully applied on patients possibly having dangers of haematology, just like other anti-blood platelet agents. For example: patients with wound, surgery, other pathology conditions or accept ASA, non-solid alcohol type anti-inflammation (NSAID), heparin, glycoprotein IIb/IIIa inhibitor or thrombus-dissolving agent. Patients should carefully pay attention to any possible symptoms of haemorrhage, including hiding haemorrhage, especially after the detection of heart-attacked inspection or surgery of the first week during the treatment. Wayfaring does not suggest using it with Clopidogrel due to the possibility of expending period of haemorrhage.
  3. Patients should stop taking Clopidogrel before the first seven days of surgery if patients choose surgery treatment and are willing not have anti-blood platelet reaction during surgery. Clopidogrel should be carefully applied on patients having tendency of haemorrhage because of its capability of lengthening bleeding period. (especially for patients having latent gastro-intestinal tract and intraocular).
  4. Patients taking Clopidogrel (regardless of taking alone or with ASA) should be informed that the required time of stopping bleeding will be longer than the usual time while injured. Patients should go to doctor immediately, if abnormal haemorrhage conditions are happened. Patients should inform doctors or dentists about taking Clopidogrel at present while operating any surgeries or adding other new drugs in advance.
  5. There are very few cases of thrombotic thrombocytopenic purpura (TTP) reported after taking Clopidogrel (sometimes it happened during the beginning of dose period). The features are reductions of anti-blood platelets and microangiopathic hemolytic anemia, sometimes, combining with neurological symptoms, unwilling kidney functions or fever. TTP is one type of diseases that needs the immediate treatment, including plasmapheresis.
  6. Clopidogrel should not be used for patients having the ST section rise acute myocardial infarction during occurring myocardial infarction within several days due to lack of clinical documents.
  7. Clopidogrel should not be recommended for use on patients with acute lack of blooded stroke (seven days after stroke) due to lack of clinical documents.
  8. Clopidogrel should be cautious for use on these patients due to limited experiences of applying on patients with unwilling kidney functions.
  9. Clopidogrel should be cautious for use on these patients due to limited experiences of applying on patients having middle-levelled unwilling liver functions possibly.
Medicine Correlation and Other Correlations
  1. Warfarin: the suggestion is not to use both of Warfarin and Clopidogrel together due to higher danger of increasing haemorrhage.
  2. Glycoprotein IIb/IIIa inhibitor: The combination of Clopidogrel and glycoprotein IIb/IIIa inhibitors will possibly increase haemorrhage dangers of wounds, surgical operations or other pathology conditions. Therefore, caution must be aware during the combination of usage.
  3. Acetylsalicylic acid (ASA): ASA certainly will not change inhibitory mechanism of clopidogrel to blood platelet agglutination. However, clopidogrel will strengthen inhibitory action for ASA to the Collagen-induced blood platelet agglutination. Nevertheless, the extended bleeding time caused by taking clopidogrel will not be increased obviously if taking 500mg ASA twice per day. The resulting haemorrhage danger will be increased due to possible correlation of the combination of clopidogrel and ASA on pharmacodynamics. Therefore, the combining usage should be cautious.
  4. Heparin: Clopidogrel will not change the hemoglutination effect of the heparin according to one reported declaration of the best healthy volunteers. Therefore, it is not necessary to adjust dosage of heparin while taking with other medicines. Heparin will not affect the inhibitory mechanism of blood platelets. The resulting haemorrhage danger will be increased due to possible correlation of the combination of clopidogrel and heparin. Therefore, the combining usage should be cautious.
  5. Thrombolytics: the myocardial infarction patient's security for safe estimating results showed that the formation rate of hemorrhageand combining with ASA, rt-PA, and heparin was similar to the one of combining with clopidogrel, rt-PA and heparin. The safety issue of combination of Clopidogrel and other thromolytics is still not yet clear. Therefore, the combining usage should be cautious.
  6. Non-solid alcohol anti-inflammation (NSAIDs): The experiment was done by healthy volunteers. The combination of naproxen and clopidogrel will cause the hiding gastro-intestinal tract hemorrhage. However, the combination with clopidogrel should be used cautiously due to lack of other NSAIDs.
  7. Other combinational treatments: there are relative practical researches under progressing in order to research the medical effect and the correlation of medical kinematics for the combination of clopidogrel and other medicines. The clinical correlation of medicine kinematics was not observed clearly while Clopidogrel combines with atenolol or nifedipine or atenolol plus nifedipine. The activeness of Clopidogrel drug will not be affected obviously combining with phenobarbital, cimetidine or oestrogen.
  8. Digoxin or theophylline characteristics of medical kinematics will not be altered by combining with clopidogrel. Acid-produced agents will not affect the absorption of Clopidogrel.
  9. Carboxylic metabolic substances of Clopidogrel can suppress the nenzyme activeness of Cytochrome the P4502C9 according to experimental demonstration of liver enzymes in human bodies. Therefore, Clopidogrel can possibly increase the density of blood plasma by products from the enzyme metabolism of Cytochrome P4502C9, such as phenytoin, tolbutamide and NSAIDs and etc. CAPRIE experiment demonstrated that it might be safe to combine phenytoin, tolbutamide and Clopidogrel together.
  10. Medicines often used by patients having many gruel shapes artery thrombus and Clopidogrel are not under researches of medical correlations besides the above drugs correlation experiments. However, the unwilling correlations in the clinical experiment were not observed obviously according to the experiment of participated patients who were taking medicines combing with other medicines including diuretic agent, beta-blocking agent, ACE inhibitor, calcium ion of the anti-medicinal agent, medicines of decreasing cholesterol, coronal blood vessel loosing agent, antidiabetic medicine (including insulin), anti-epilepsy medicine, hormone supplying and treating medicines and GPIIb/IIIa anti-medicinal agent.
Unwilling Respondences
The most common side effects are haemorrhage, such as stasis wounds, haematoma, nosebleed, haematuria, gastric haemorrhage or stomach haemorrhage. There are few clinical cases carrying out with haemorrhages in eyes, heads, lungs or joints.
 
 
Tramadol
Indication: Moderate to serious anxious chronic ache
Product COA: demanded product COA
Consulting Phone Line: 07-591-9568
Product Instruction
This product has double twitches mechanism of opium and non-opium. Its effect is on the central nervous system and can suppress stimulates then represent the analgesia function. There are non-breath inhibitory and intestines inhibitory functions in therapeutic dose (400mg everyday).
Bans of Product
  1. Acute poison will be caused by combining with ethyl alcohol, sleeping pill, pain-killer or mental agent.
  2. Danger of taking medicines should be considered during pregnant and breeding.
  3. It should be used cautiously for patients who are sensitive to sleeping or anaesthetic pills containing opium.
Medicine Correlation and Other Correlations
  1. Ethyl alcohols, ananesthetics, hypnotics, sedative, three links class anti-despondent medicinal preparations (TCA) and so on might increase the side effects of this medicine (including central nervous system suppression and initiating epilepsy and etc). Therefore, it must be used cautiously.
  2. This medicine is banned for injection when patients are using the single amine oxidizes (MAO) suppressing treatment.
 
 

Atorvastatin
Indication: High cholesterol blood disease, high three acids glycerine lipemi
Product COA: demanded product COA
Consulting Phone Line: 07-591-9568

Product Instruction
Atorvastatin can be the assistant treatment of diet control to reduce total cholesterol, low density of lipoprotein cholesterol (LDL- cholesterol), lipoprotein (apolipoprotein B) and triglyceride of primary high cholesterol blood diseases (heterogeneous zygote family and non-family high cholesterol blood disease) and mixed high lipemia (Fredrickson IIa and IIb) patients. As well, it can increase high density of lipoprotein cholesterol (HDL- cholesterol) of patients, and cure patients with increased density of serum triglyceride (Fredrickson IV). Nevertheless, it is also useful for patients of primary beta lipoprotein unusual blood disease (Fredrickson III) and having unwilling results of the diet treatment. Atorvastatin can also reduce the total cholesterol and low density cholesterol for patients of the same type of zygote family high cholesterol blood disease, during undesirable results of diet and other non-drugs treatments.

Bans of Product
Atorvastatin is prohibited to be applied on patients: (1) who are allergic to any ingredients of this medicine, (2) who are having active liver complaint or unclear-reason blood serum amino shift enzyme with constant rise to surpass on the normal limiting value 3 times above, (3) who are pregnant, breeding, or likely pregnant without confirmation. The woman of child-bearing age can only take this medicine while it is impossible to have pregnancy and understandings of potential risky situations are clear.

Special Warning and Attention of Usage

Influence to liver: There were reports of blood serum density having amino shifting enzyme with levels from moderate to high (higher than normal limiting value 3 times)after taking atorvastatin. These are similar to other felling blood fats medicinal agents. Liver functions were under detecting frequently while using atorvastatin10, 20, 40 and the 80mg dosage, during clinical tests before and after atorvastatin was in markets. 0.7% Patients having atorvastatin approximately appears phenomenon of increasing blood serum density of the amino shifting enzyme (two or many times higher than normal limiting value 3 times) in these clinical experiments. These unusual formation rates were 0.2%, 0.2%, 0.6% and 2.3% while Atorvastatin dosages were 10, 20, 40 or 80mg respectively. The rising index of liver functions will not usually accompany with Huang Tanhuo or other clinical symptoms or features. The density of amino shifting enzyme returns to the foundation value of the previous treatment after reducing Atorvastatin dosage or stopping taking this medicine. The majority of patients after reducing the dosage can be healed continuously without sequela. Patients should do periodic liver function checking before the Atorvastatin treatment. These observations should be treated as liver function inspections, while patients appear to have symptoms or attributes of liver damages. Patients having rising blood serum density of amino shifting enzyme should accept checking continuously until reaching the normal standards. It must reduce the dosage or stop taking this medicine if ALT or AST surpass on above normal limiting value 3 times. Atorvastatin might possibly cause the increased density of amino shift enzyme. Patients with massively drinking and/or having suffered from liver complaint should take this medicine cautiously. Patients with active liver complaint or unclear-reasoned increasing blood serum amino shifting enzyme should stop taking this medicine.

Influence to Skeletal Muscle: There were reports about that patients taking Atorvastatin had muscle aches. The definition of myopathy is the muscle ache or no energy of muscle, mealwhile, the density of creatine phosphokinase (CPK) surpasses 10 times of the normal limiting value. These observations should be treated as myopathy once patients feel about filling muscle ache, muscle tenderness or incapability and/or CPK obvious elevation. Patients should be informed once appearing unclear-reasonable muscle ache, tenderness or incapability, especially for general malaise or having a fever, and must inform doctor immediately. The Atorvastatin treatment must be stopped when the CPK density obviously rises as well as the determination or suspicion of having myopathy are defined. The risk of myopathy will be increased when these types of drugs are used with Cyclosporine, fibric acid derivatives, erythromycin, niacin or the azole type of anti-mildew microbial inoculum. Many of these drugs can suppress the metabolism and/or medicine transports of cytochrome P450 3A4. Atorvastatin possesses biotransformation throughout CYP 3A4. Doctors should consider benefits and risks carefully while using the treatment of combining Atorvastatin with fibric acid derivatives, erythromycin, immunity inhibitor, and niacin therapy of azole type of anti-mildew microbial inoculums or falling blood fats dosage. Patients should be carefully detected to have observations of whether muscle aches, tenderness or incapability and so on or not during the treatment, particularly in the beginning of the treatment or within several months of increasing dosages of any medicines. The regular detecting CPK might be considerable under this circumstance. However, this kind of detection certainly cannot prevent the occurrence of serious myopathy. Atorvastatin might possibly cause the rise of CPK density. There were few reports related to complications of Rhabdomyolysis and Myoglobinuria-secondary-acute Renal Failure for Atorvastatin and some similar types of drugs. The Atorvastatin treatment must be suspended or terminated if patients occurs serious acute conditions related to myopathy, or has dangerous factors causing by striated muscle dissolution (for example, serious acute infection, hypotension, significant surgery, flesh wound, serious metabolism, internal secretion and electrolyte disease, as well as not yet good control epileptic paroxysm).

Medicine Correlation and Other Correlation
This type of drugs if using with Cyclosporine, fibric acid derivatives, erythromycin, niacin or azole kind of anti-mildew microbial inoculum together, will increase the danger of myopathy.

Unwilling Respondences
It has good tolerance. Less than 2% of patients stop taking this medicine due to side effects. The common side effects are constipation, stomach and intestines flatus, unwilling digestion and abdominal pain.

 
 
Risperidone
Indication: the correlation symptom causing by spirit exception, double extremes being hot-tempered of manifests of illness
Product COA: demanded product COA
Consulting Phone Line:07-591-9568
Product Instruction
  1. Risperdone might treat various types of schizophrenia patients, firstly including neurosis, acute schizophrenia worsens, chronic schizophrenia and other unusual mental conditions, that include positive symptoms (for example: illusion, delusion, ponder barrier, hostility, oversuspicious) and/or negative symptoms (for example, sluggish emotion, flinches of mood and social relations, deficient conversation).
  2. Risperdone also can reduce the emotion symptoms following with schizophrenia (for example, despondent, ashamed feeling, anxious). As for patients having responses in the initial treatment, Risperdone also can continue in maintaining clinical progress during the treatment.
  3. Risperdone might cure mixing behaviors of patients with loses behavior of Dementia. These symptoms of patients have attacked (explosive opinion, body conflict) activities barriers (mood excitement, insatiability) or symptoms of obvious neurosis.
  4. Risperdone can be used for Syndrome attack of double extremes diseases. These manifest typical symptoms can be mood soaring, inflation or anger, conceited, sleep demand reduction, oppression of language, running thoughts, attention dispersion or unwell judgment, including bahaviors of breaking off or aggressive.
  5. Risperdone might be applied to children, youths or sadults with the low IQ or intelligence lower than the averaged intelligence. It can also heal patients with breaking behaviors with moral characters and others. These patients possess destructive behaviors (for example, aggressiveness, impulse, self-injuried behavior).
Bans of Product
Stopping using this medicine once found allergy to it.
Special Warning and Attention of Usage
  1. It is possible to produce (posture nature) hypotension due to the alpha-blocking function of Risperdone. Therefore, the dosage in the beginning period should be adjusted carefully. Risperdal should be used carefully for patients having heart blood vessel diseases (for example, heart failure, myocardial infarction, conduction exception, dehydration, blood volume reduction or blood vessel of brain disease).
  2. It will be able to cause the hangfire dyskinesia due to medicines containing many Pakistan amine acceptors of the anti-function. The characteristics are rhythmic dependent movement, especially for face and/or tongue. The symptoms of the cone outer diameter have been reported as the dangerous factor of hangfire dyskinesia.
  3. The risk of inducing tardive dyskinesia is lower than the one caused by other traditional anti-schizophrenia medicines because Risperdone is not easier to cause Extrapyramidal syndrome. Treatments using all types of anti-neuroses medicines should be considered to be stopped once tardive dyskinesia is occurred. The use of tradition anti-schizophrenia medicines will conduct Neuroleptic Malignant Syndrome (NMS). The characteristics are fever, catalepsy, autonomic nervous system dysregulation, consciousness revolution and the increasing density of CPK. All anti-neuroses medicines including Risperdone must be stopped using If these situations were happened.
  4. It must be cautious while applying prescriptions of risperdone to Parkinson’s patients because it can possibly worsen symptoms of Parkinson disease.
  5. Traditional anti-schizophrenia medicines were confirmed that they can reduce the epileptic paroxysm threshold number. It should be carefully used while treating epilepsy patients.
  6. Patients should be informed to avoid from being overweight due to possibility of overweight.
Medicine Correlation and Other Correlations
  1. The risk of Risperdone combining with other medicines is not yet estimated systematically It should be cautious while combining with other medicines functioning on central nervous system because Risperdone functions mainly on the central nervous system.
  2. Risperdone can possibly oppress the effects of anti-levodopa and other multi-Pakistan amine agents.
  3. Carbamazepine will decrease the effective anti-neurosis medical ingredients of Risperdone in the blood plasma. This result is also for others chemical compounds which are capable of inducing liver enzyme. Therefore, Risperdone dosage should be adjusted again, sometimes, weight loss is needed when carbamazepine and medicines of inducing liver enzyme were stopping taken. Phenothiazines, three links anti-despondent medicinal agent and certain beta-blocking agent can possibly enhance the blood density of Risperdone, but certainly not belonging to the partial activeness of anti-neurosis function.
  4. Amitriptyline will not affect the medicine dynamics or the partial activeness functionof anti- neurosis of Risperdone. Cimetidine and ranitidine will increase the body using rate of Risperdone, but only involving the partial activeness function of anti-neurosis.
  5. Fluoxetine, paroxetine and CYP 2D6 inhibitor will increase the blood the density of Risperdone, but have small effects on the partial activeness function of resistance neurosis. The combination of plasma proteins and Risperdone will be affected while Risperdone was used with medicines having high uniting rate with proteins. Food will affect the absorption of Risperdone.